Champions Oncology annual gross margin
2020
2021
2022
2023
2024
2025
2026
Champions Oncology Gross Margin Growth & History (CSBR)
Champions Oncology's gross margin was 48.00% for fiscal 2026.
View full Champions Oncology company overviewChampions Oncology annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-30 | 48.00% | −2.14 pp |
| 2025 | 2025-04-30 | 50.15% | +8.77 pp |
| 2024 | 2024-04-30 | 41.38% | −3.80 pp |
| 2023 | 2023-04-30 | 45.18% | −6.70 pp |
| 2022 | 2022-04-30 | 51.88% | +4.13 pp |
| 2021 | 2021-04-30 | 47.74% | +0.67 pp |
| 2020 | 2020-04-30 | 47.08% | — |
Champions Oncology quarterly gross margin
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2026 | 2026-04-30 | 50.79% | +9.65 pp |
| Q3 2026 | 2026-01-31 | 46.65% | −14.51 pp |
| Q2 2026 | 2025-10-31 | 51.70% | +6.77 pp |
| Q1 2026 | 2025-07-31 | 42.87% | −6.83 pp |
| Q4 2025 | 2025-04-30 | 41.14% | −7.08 pp |
| Q3 2025 | 2025-01-31 | 61.17% | +26.47 pp |
| Q2 2025 | 2024-10-31 | 44.93% | +2.12 pp |
| Q1 2025 | 2024-07-31 | 49.70% | +10.88 pp |
| Q4 2024 | 2024-04-30 | 48.22% | +4.36 pp |
| Q3 2024 | 2024-01-31 | 34.70% | −5.03 pp |
| Q2 2024 | 2023-10-31 | 42.82% | −5.07 pp |
| Q1 2024 | 2023-07-31 | 38.83% | −9.87 pp |
| Q4 2023 | 2023-04-30 | 43.86% | −7.83 pp |
| Q3 2023 | 2023-01-31 | 39.72% | −11.72 pp |
| Q2 2023 | 2022-10-31 | 47.88% | −4.53 pp |
| Q1 2023 | 2022-07-31 | 48.69% | −3.35 pp |
| Q4 2022 | 2022-04-30 | 51.69% | +7.00 pp |
| Q3 2022 | 2022-01-31 | 51.44% | −5.80 pp |
| Q2 2022 | 2021-10-31 | 52.41% | +8.20 pp |
| Q1 2022 | 2021-07-31 | 52.05% | +7.94 pp |
| Q4 2021 | 2021-04-30 | 44.69% | +2.32 pp |
| Q3 2021 | 2021-01-31 | 57.24% | +5.23 pp |
| Q2 2021 | 2020-10-31 | 44.21% | −4.89 pp |
| Q1 2021 | 2020-07-31 | 44.11% | −0.20 pp |
| Q4 2020 | 2020-04-30 | 42.37% | — |
| Q3 2020 | 2020-01-31 | 52.01% | +5.34 pp |
| Q2 2020 | 2019-10-31 | 49.10% | +0.66 pp |
| Q1 2020 | 2019-07-31 | 44.31% | −6.17 pp |
| Q3 2019 | 2019-01-31 | 46.67% | −4.67 pp |
| Q2 2019 | 2018-10-31 | 48.44% | −0.57 pp |
| Q1 2019 | 2018-07-31 | 50.47% | +2.97 pp |
| Q3 2018 | 2018-01-31 | 51.34% | — |
| Q2 2018 | 2017-10-31 | 49.01% | — |
| Q1 2018 | 2017-07-31 | 47.51% | — |
Champions Oncology gross margin trends
Over the last five fiscal years, Champions Oncology's gross margin increased from 47.74% to 48.00%, a change of +0.26 percentage points. The latest reported quarter, Q4 2026, shows 50.79%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Champions Oncology source filings ↗